Erytech Pharma SA (DE:2E4A)

Erytech Pharma SA (2E4A) Income Statement


Erytech Pharma SA Income Statement

Last quarter (Q4 2022), Erytech Pharma SA's total revenue was €0.00, a decrease of ― from the same quarter last year. In Q4, Erytech Pharma SA's net income was €5.94M. See Erytech Pharma SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-€ 0.00€ 0.00€ 0.00€ 0.00€ 0.00
Cost of Revenue
---€ 57.58M€ 52.19M€ 33.47M
Gross Profit
---€ -57.58M€ -52.19M€ -33.47M
Operating Expense
€ 27.15M€ 27.15M€ 56.52M€ 68.83M€ 11.88M€ 10.15M
Operating Income
€ -27.15M€ -27.15M€ -56.52M€ -68.83M€ -64.07M€ -43.62M
Net Non Operating Interest Income Expense
€ 3.09M€ 3.09M€ 1.54M€ -5.12M€ 1.41M€ 5.40M
Other Income Expense
€ -2.87M€ 24.35M€ 1.18M€ 652.00K--
Pretax Income
€ 293.00K€ 293.00K€ -53.80M€ -73.30M€ -62.66M€ -38.22M
Tax Provision
€ 521.00K€ 521.00K€ 2.00K€ 3.00K€ -1.00K€ 2.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
€ -227.00K€ -227.00K€ -53.80M€ -73.30M€ -62.66M€ -38.22M
Basic EPS
Diluted EPS
Basic Average Shares
Diluted Average Shares
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
--€ 1.13M€ 1.07M€ 2.41M€ 2.38M
Total Expenses
€ 27.15M€ 27.15M€ 56.52M€ 68.83M€ 64.07M€ 43.62M
Net Income From Continuing And Discontinued Operation
€ -227.00K€ -227.00K€ -53.80M€ -73.30M€ -62.66M€ -38.22M
Normalized Income
€ 1.49M€ -14.84M€ -54.66M€ -73.77M€ -62.66M€ -38.22M
Interest Expense
€ 1.36M€ 1.36M€ 2.14M€ 2.16M€ 491.00K€ 9.00K
€ 1.66M€ 1.66M€ -51.66M€ -71.14M€ -62.17M€ -38.22M
€ 1.66M€ 1.66M€ -46.28M€ -66.14M€ -57.95M€ -37.42M
Currency in EUR

Erytech Pharma SA Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis